HIGHLIGHTS   |  April 30, 2020   FDA Grants RMAT Designation to Tisagenlecleucel for Relapsed/Refractory Follicular Lymphoma The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma. Read more ADVERTISEMENT   ILROG Recommends Alternative Radiation Treatment Schemes in Blood Cancer During COVID-19 Pandemic The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic. Read more   In Case You Missed It

New Genetic Structural Variants Identified in Childhood Leukemias Previously unrecognized genetic structural variants in childhood leukemias could be used to evaluate the presence of minimal residual disease during chemotherapy and help to determine response to various therapies. Read more